Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

<strong>Background<br></strong> Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of major cardiova...

Full description

Bibliographic Details
Main Authors:	Nazarzadeh, M, Bidel, Z, Canoy, D, Copland, E, Bennett, DA, Dehghan, A, Davey Smith, G, Holman, RR, Woodward, M, Gupta, A, Adler, AI, Wamil, M, Sattar, N, Cushman, WC, McManus, RJ, Teo, K, Davis, BR, Chalmers, J, Pepine, CJ, Rahimi, K
Other Authors:	Blood Pressure Lowering Treatment Trialists' Collaboration
Format:	Journal article
Language:	English
Published:	Elsevier 2022

Similar Items

The Blood Pressure Lowering Treatment Trialists’ Collaboration: methodological clarifications of recent reports
by: Nazarzadeh, M, et al.
Published: (2022)

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
by: Rahimi, K, et al.
Published: (2021)

Sex-specific effects of blood pressure lowering pharmacotherapy for the prevention of cardiovascular disease: an individual participant-level data meta-analysis
by: Bidel, Z, et al.
Published: (2023)

Blood pressure treatment: how low should you go? – Authors' reply
by: Rahimi, K, et al.
Published: (2021)

Blood pressure meta-analysis highlights an implementation gap - authors' reply
by: Rahimi, K, et al.
Published: (2022)

Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis
by: Nazarzadeh Larzjan, M, et al.
Published: (2021)

How much lowering of blood pressure is required to prevent cardiovascular disease in patients with and without previous cardiovascular disease?
by: Canoy, D, et al.
Published: (2022)

Stratification of diabetes in the context of comorbidities, using representation learning and topological data analysis
by: Wamil, M, et al.
Published: (2023)

Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes - authors' reply
by: Nazarzadeh, M, et al.
Published: (2022)

Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: an individual participant data meta-analysis
by: Pinho-Gomes, A-C, et al.
Published: (2021)

Stratification of diabetes in the context of comorbidities, using representation learning and topological data analysis
by: Malgorzata Wamil, et al.
Published: (2023-07-01)

Effects of blood pressure-lowering drugs in heart failure: a systematic review and meta-analysis of randomized controlled trials
by: Pinho-Gomes, A, et al.
Published: (2019)

Genetic susceptibility, elevated blood pressure and risk of atrial fibrillation: a Mendelian randomization study
by: Nazarzadeh Larzjan, M, et al.
Published: (2021)

Genetic susceptibility, elevated blood pressure and risk of atrial fibrillation
by: Nazarzadeh, M, et al.
Published: (2020)

Genetic susceptibility, elevated blood pressure and risk of atrial fibrillation
by: Nazarzadeh, M, et al.
Published: (2021)

Increased risk of incident heart failure and all-cause mortality in insulin-resistant people with type 2 diabetes in the United Kingdom Prospective Diabetes Study (UKPDS)
by: Wamil, M, et al.
Published: (2020)

Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89
by: Wamil, M, et al.
Published: (2021)

Blood pressure and risk of venous thromboembolism: a cohort analysis of 5.5 million UK adults and Mendelian randomization studies
by: Nazarzadeh, M, et al.
Published: (2022)

Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study
by: Milad Nazarzadeh, et al.
Published: (2021-03-01)

Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials
by: Canoy, D, et al.
Published: (2022)

Plasma lipids and risk of aortic valve stenosis: A Mendelian randomization study
by: Nazarzadeh, M, et al.
Published: (2020)

Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC)
by: Rahimi, K, et al.
Published: (2019)

Antihypertensive treatment and risk of cancer: individual participant data meta-analysis of randomized clinical trials
by: Narzarzedah, M, et al.
Published: (2021)

Systolic blood pressure, chronic obstructive pulmonary disease and cardiovascular risk
by: Rao, S, et al.
Published: (2023)

Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study
by: Tran, J, et al.
Published: (2018)

Long-term exposure to elevated systolic blood pressure in predicting incident cardiovascular disease: evidence from large-scale routine electronic health records
by: Solares, JR, et al.
Published: (2019)

Systolic blood pressure and cardiovascular risk in patients with diabetes: a prospective cohort study
by: Rao, S, et al.
Published: (2022)

Heterogeneity between genetic variants as a proxy for pleiotropy in mendelian randomization - reply
by: Nazarzadeh, M, et al.
Published: (2019)

Mendelian randomization of plasma lipids and aortic valve stenosis: the importance of outlier variants and population stratification
by: Nazarzadeh, M, et al.
Published: (2020)

Limitations of subgroup analysis of underpowered clinical trials for making causal inference about treatment effects
by: Nazarzadeh, M, et al.
Published: (2020)

Intensive blood pressure lowering and risk of diabetes: Friend or foe?
by: Nazarzadeh, M, et al.
Published: (2019)

Elevated blood pressure, antihypertensive medications and bone health in the population: revisiting old hypotheses and exploring future research directions
by: Canoy, D, et al.
Published: (2021)

Current practice of usual clinic blood pressure measurement in people with and without diabetes: a survey and prospective ‘mystery shopper’ study in UK primary care
by: Stevens, S, et al.
Published: (2018)

Blood pressure-lowering treatment lowers mortality and cardiovascular disease risk, but whether effects differ at an arbitrary threshold of 140 mm Hg systolic blood pressure requires further research
by: Canoy, D, et al.
Published: (2018)

A way to a woman's heart might be through her bones
by: Canoy, D, et al.
Published: (2021)

Systolic blood pressure and risk of valvular heart disease: a mendelian randomization study
by: Nazarzadeh, M, et al.
Published: (2019)

Systolic blood pressure and risk of valvular heart disease: A mendelian randomization study
by: Nazarzadeh, M, et al.
Published: (2019)

Patients' journey of care following incident heart failure: diagnostic tests, treatments and care pathways in 93,000 patients
by: Conrad, N, et al.
Published: (2018)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
by: Wamil, M, et al.
Published: (2020)

Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study.
by: Jenny Tran, et al.
Published: (2018-03-01)